Benitec, Ltd.

Hot mouse technology used for diabetes, obesity therapies

Published in Medicine and Law Weekly, March 11th, 2005

Benitec, Ltd., announced the execution of an exclusive license agreement with the Garvan Institute of Medical Research in Sydney, Australia.

Under the terms of the license agreement, Benitec has exclusive rights to develop RNA interference (RNAi)-based drugs for diabetes, obesity, and related disorders. Benitec and Garvan have also entered into discussions for a research collaboration to develop these novel therapies.

Both the licensed intellectual property and the proposed research collaboration focus on the c-Cbl gene (pronounced "c-cybil") as a drug target for diabetes and obesity. The Garvan Institute recently made international headlines with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2005-03-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry